Clinical
AbbVie/Roche's Venclexta produces complete remission in 10% ...
AbbVie/Roche's Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation, a sub-group who do not respond well
